GSK has teamed up with the University of Oxford on a programme that will try to identify the molecular changes in cells in precancerous stages that could form the basis of vaccines to prevent full ...

The move comes five months after one of the company’s top executives was killed after being shot as he walked to an investor conference in ...

GlaxoSmithKline wants to sell more than a ... the heart of the UK's 'golden triangle', extending between London, Oxford and Cambridge, which houses the lion's share of the country's life science ...

“This is a high-quality study that stands out mainly for its sample size. The results confirm previous findings that people with a history of cold sores have a higher risk of developing Alzheimer’s ...

Those are just a few of the classic storylines Lifetime movie fans expect to see when they switch on the TV, and, this summer, GSK is adding another real-life danger to Lifetime's lineup ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...

GSK said combinations of its blood-cancer treatment, Blenrep, have been approved by Japan’s Ministry of Health, and that it expects more approvals through the year. The U.K. pharma company said ...

The FDA has lifted its 19-month clinical hold on vaginal yeast infection drug Brexafemme (ibrexafungerp), according to the treatment's developer Scynexis. In its first-quarter report, the Jersey ...

GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B British pharmaceutical company GSK (GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin ...